More about

Teprotumumab

News
June 24, 2021
5 min read
Save

Teprotumumab effective, safe after 1 year in clinical use

Teprotumumab effective, safe after 1 year in clinical use

Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.

News
June 01, 2021
12 min read
Save

Thyroid eye disease managed jointly by ophthalmologists and endocrinologists

Thyroid eye disease managed jointly by ophthalmologists and endocrinologists

Not everyone can agree on what to call thyroid eye disease.

News
June 01, 2021
2 min read
Save

Multidisciplinary management approach needed for thyroid eye disease

Multidisciplinary management approach needed for thyroid eye disease

Thyroid eye disease was first described by Robert James Graves, FRCS, an Irish surgeon who recognized the association of hyperthyroidism with exophthalmos in 1835. Even today, many use Graves’ ophthalmopathy when discussing this disease.

News
May 14, 2021
2 min watch
Save

VIDEO: Teprotumumab useful in patients with thyroid eye disease

VIDEO: Teprotumumab useful in patients with thyroid eye disease

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Roger A. Dailey, MD, discusses outcomes in patients treated for thyroid eye disease with traditional methods and teprotumumab.

News
May 08, 2021
1 min watch
Save

VIDEO: Thyroid eye disease management changed with teprotumumab approval

VIDEO: Thyroid eye disease management changed with teprotumumab approval

WAILEA, Hawaii — In this video from Hawaiian Eye, Wendy W. Lee, MD, and Roger A. Dailey, MD, discuss the latest information surrounding diagnosis and management of thyroid eye disease.

News
April 23, 2021
3 min read
Save

Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease

Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease

Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.

News
April 02, 2021
1 min read
Save

Horizon receives authorization to increase Tepezza production

Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease, according to a press release.

News
March 11, 2021
2 min read
Save

Shortage of Tepezza disrupts treatment of thyroid eye disease

Shortage of Tepezza disrupts treatment of thyroid eye disease

The COVID-19 pandemic has abruptly affected drug manufacturing in the United States. This now includes the production of Tepezza, the only FDA-approved medical therapy for thyroid eye disease.

News
December 16, 2020
2 min read
Save

Number of FDA new molecular entity approvals in 2020 similar to 2019

Number of FDA new molecular entity approvals in 2020 similar to 2019

Despite the COVID-19 pandemic, the FDA approved 47 new molecular entities in 2020, including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

News
November 20, 2020
2 min read
Save

Data show longer-term efficacy of teprotumumab in severe, less severe thyroid eye disease

Additional data from the OPTIC-X extension trial and pooled analysis of phase 2 and 3 trial data confirm the efficacy of teprotumumab for the treatment of thyroid eye disease in the longer term and at different degrees of disease severity.

View more